Drug Search Results
More Filters [+]

LZ-001

Alternative Names: LZ-001, LZ 001, LZ001
Latest Update: None
Latest Update Note: None

Product Description

Livzon Pharma is developing LZ001 tablets, a small molecule ROS1/NTRK/ALK multi-kinase Inhibitor.

Mechanisms of Action: ROS1 Inhibitor,ALK Inhibitor

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Livzon Pharmaceutical Group Co., Ltd.
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for LZ-001

Countries in Clinic: China

Active Clinical Trial Count: 1

Highest Development Phases

Phase 1: Oncology Solid Tumor Unspecified

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

CTR20221852

P1

Not yet recruiting

Oncology Solid Tumor Unspecified

None

Recent News Events

Date

Type

Title